Australian CRO Avance Clinical has said that Australia’s fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites, as well as the attractive 40% Government rebate on clinical trial spend, means Avance is uniquely positioned to deliver rapid results for urgent COVID-19 trials.

Avance Clinical offers 20-years of experience in the CRO sector and has conducted vaccine and infectious diseases trials in the past 5 years. Avance is clearly the CRO of choice for trials targeting COVID-19.

“Importantly, the more than 40% R&D cash rebate from the Australian Government and the attractive current exchange rate, makes Australia one the most cost-effective destinations for conducting clinical trials,” said Avance Clinical CEO Yvonne Lungershausen.

Australia’s reputation for scientific and research excellence, its advanced healthcare, and the opportunity to access patients in a less clinical trial competitive environment further reinforces its advantage as a destination for current COVID-19 trials.

“Our depth of expertise and knowledge in the area makes us the CRO of choice for any biotech looking to develop treatments for COVID-19,” said Ben Edwards, Avance’s Chief Strategy Officer.

Ms Lungershausen said, “Our team’s experience in working with remotely based clients and clinical service providers and our virtual communication systems and processes place us in a clear position of strength in maintaining the momentum for our current projects”.

“Our team is very much accustomed to remote communication and management of projects,” said Mr Edwards.

The Avance Clinical operations team maintains constant communication with trial sites, receiving the latest information on ongoing changes in procedures and effectively managing the activities relating to the projects being managed by Avance.

“Avance Clinical has a range of tools available to support the sites and our clients to successfully complete their trials during this challenging time. These will be carefully managed to ensure study compliance,” said Ms Lungershausen.